Page 250 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 9
18. Eertink JJ, Arens AIJ, Huijbregts JE, et al. HOVON imaging workgroup. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. Eur J Nucl Med Mol Imaging. 2022 Feb; 49(3):943-952.
19. HOVON Lymfoom werkgroep. Richtlijn diffuus grootcellig B-cel non-Hodgkin lymfoom. Amsterdam: HOVON centraal bureau; 2021. Available from: https://hematologienederland.nl/wp- content/uploads/2021/10/Richtlijn-DLBCL-_NVvH.pdf.
20. Persky DO, Li H, Stephens DM, et al. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020 Sep 10;38(26):3003-3011. Erratum in: J Clin Oncol. 2020 Oct 10;38(29):3459.
21. Dührsen U, Müller S, Hertenstein B, et al. PETAL Trial Investigators. Positron Emission Tomography- Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2018;36(20):2024-2034.
22. Greuter M, Eertink JJ, Jongeneel G, et al. PETRA consortium. Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6)382-392.
23. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184-4190. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896.
24. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-3496.
25. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. J Clin Oncol. 2017 Feb 10;35(5):544-551.
26. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800-1808. Erratum in: Blood. 2018 Feb 1;131(5):587-588.
27. Lugtenburg PJ, Zijlstra JM, Doorduijn JK, et al. Dutch HOVON group. Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. Br J Haematol. 2019 Nov;187(3):347-355.
28. Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013 Nov;98(11):1726-1731.
29. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013 Jun 10;31(17):2103-2109.
30. Zinzani PL, Pellegrini C, Argnani L, Broccoli A. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. Haematologica. 2016 Sep;101(9):e385-386.
31. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531-2544.
32. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan;20(1):31-42.
33. Schuster SJ, Bishop MR, Tam CS, et al. JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan 3;380(1):45-56.
34. Neelapu SS, Dickinson M, Sci D, et al. Interim Analysis of ZUMA-12: A phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL). Blood. 2020;136 (Suppl 1):49. Abstract 626.
35. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021 Jun 20;39(18):1959-1970.
248